NanoViricides anticipates that it will be using the space in the near future for laboratory facilities and cGMP production of its nanoviricides drug candidates against various viral diseases.
It is working with various firms capable to built cGMP manufacturing at this facility in a timely manner.
NanoViricides CEO Eugene Seymour said they believe they will be achieving the cGMP manufacturing and lab space they need without capital expenditure from the company’s current cash reserves.
"We are making progress in clearing a major hurdle in our path towards FDA submissions and human clinical development of our drug candidates," Seymour said.
NanoViricides is developing the pre-IND application for clinical candidate for Influenza.